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In vitro antitumour activity of the novel imidazoisoquinoline SDZ 62-434
V.G. Brunton & P. Workman
Cancer Research Campaign Laboratories, CRC Department of Medical Oncology, University of Glasgow, Garscube Estate,
Switchback Road, Bearsden, Glasgow, G61 IBD, UK.
Summary The novel imidazoisoquinoline SDZ 62-434, originally identified as a platelet-activating factor
(PAF) antagonist, has antiproliferative activity in a range of cell lines from human solid and haematological
malignancies. Using an MTT cytotoxicity assay, IC50 values of 5 iLM- Il l M were observed following a 24 h
exposure. Similar results were obtained using a clonogenic assay. The HT29 colon adenocarcinoma was
particularly sensitive while the MCF-7 breast carcinoma was the most resistant in our panel. Only a 2-3 fold
cross-resistance was seen in the doxorubicin and cisplatin resistant variants of the A2780 ovarian carcinoma;
the drug did not modulate sensitivity to doxorubicin in either parent or resistant lines. No cross-resistance to
SDZ 62-434 was seen in a doxorubicin-resistant MCF-7 variant. Cytotoxicity was not due to non-specific
membrane lysis. The potent PAF antagonist WEB 2086 did not modulate SDZ 62-434 cytotoxicity, indicating
no role for PAF receptors. Precursor incorporation studies in A2780 cells showed that DNA synthesis was
inhibited more effectively than protein synthesis while RNA synthesis was unaffected. SDZ 62-434 inhibited
both bombesin and platelet-derived growth factor-induced DNA synthesis in quiescent Swiss 3T3 cells. This
suggests a possible role for SDZ 62-434 as an inhibitor of signal transduction in cancer cells.
The ether lipids are members of a group of new antitumour
agents which appear to have no direct effects on either DNA
function or synthesis. They exert a wide range of actions such
as macrophage activation (Berdel et al., 1980) and changes in
membrane structure and permeability (Noseda et al., 1988;
Dive et al., 1991), as well as having direct cytotoxic effects
against tumour cells in vitro (reviewed in Berdel, 1991).
Although effects on signal transduction in cancer cells are
thought to be important (Seewald et al., 1990; Uberall et al.,
1991) and the rate of uptake by endocytosis is believed to
influence cytotoxic selectivity (Bazill & Dexter, 1990; Work-
man, 1991), the precise mechanism of action of ether lipids
remains to be elucidated. Due to their close structural re-
lationship to platelet-activating factor (PAF), studies with
various PAF receptor antagonists were undertaken to deter-
mine whether the antitumour activity of ether lipids involved
interaction with PAF receptors (Berdel et al., 1987; Bazill &
Dexter, 1989; Workman et al., 1991). Together with
structure-activity relationships (Danhauser et al., 1987) and
studies with steroenantiomers of PAF (Lohmeyer & Work-
man, 1992) these investigations have ruled out a functional
role for PAF receptors in the cytotoxicity of ether lipids.
However, in the course of these investigations Berdel and
co-workers (1987) found cytotoxicity profiles comparable to
ether lipids with two lipid PAF receptor antagonists, CV
3988 (Terashita et al., 1983) and SRI 63-154 (Berdel et al.,
1987). These two compounds are structurally related to the
ether lipids. In contrast a structurally unrelated PAF receptor
antagonist, WEB 2086 (Casals-Stenzel et al., 1987), was
found to be non-cytotoxic in a human promyelocytic
leukaemia cell line (Workman et al., 1991). Nevertheless, four
other chemical classes of PAF antagonists developed by the
Sandoz Research Institute were found to be cytotoxic in a
number of different human tumour cell lines (Danhauser-
Riedl et al., 1991). One such group was a series of imida-
zoisoquinolines, which were originally designed as orally
active, non-charged PAF antagonists based on PAF as a
template (Houlihan et al., 1989). From this group SDZ 62-
434 (Figure 1) emerged as a candidate for clinical evaluation
and has now entered a Phase 1 trial in Cambridge under the
auspices of the Cancer Research Campaign.
Despite its interesting in vitro cytotoxicity towards tumour
cells and its novel structure little is known about the mode of
action of SDZ 62-434. It has been reported to increase
tumour necrosis factor secretion from human monocytes
(Valone & Ruis, 1992). It also inhibits the growth of the
transplanted MethA sarcoma and prolongs survival of
tumour-bearing mice in a fasion which suggests an involve-
ment of macrophage-induced cytotoxicity (Houlihan, per-
sonal communication). However, the mechanism of direct
non-immune mediated antitumour effects is completely un-
known. Here we report our initial studies on the antipro-
liferative activity of this new anticancer agent.
Materials and methods
Materials
SDZ 62-434 dihydrochloride was a kind gift from Dr Bill
Houlihan (Sandoz Research Institute, East Hanover, New
Jersey) and WEB 2086 a kind gift from Dr Karl-Heinz
Weber (Boehringer Ingelheim, Ingelheim am Rhein, FRG).
[3H]Thymidine (5 Ci mmol '), [3H]leucine (57 Ci mmol-1),
[3H]uridine (47Cimmol ') and [5"Cr]chromate (sodium salt,
250 mCi mg-' chromium) were obtained from Amersham
Ltd (Amersham, UK). Platelet-derived growth factor
(PDGF) was purchased from Boehringer Mannheim (BCL,
Lewes, UK) and bombesin from Sigma Chemical Co. (Poole,
Dorset, UK).
Cells
A range of human cell lines were used in the cytotoxicity
studies: HL60 (promyelocytic leukaemia), K562 (chronic
myelogenous leukaemia), U937 (histiocytic lymphoma),
A2780 (ovarian carcinoma), MCF-7 (breast adenocarcin-
oma), H69 (small cell lung carcinoma), L-DAN (squamous
non-small lung carcinoma), HT29 (colon adencarcinoma),
LoVo (colon adenocarcinoma), MOG-G-CCM (astrocy-
toma), SB-1 8 (astrocytoma), MOG-G-UVW (astrocytoma)
and U251 (glioblastoma). Mouse Swiss 3T3 cells were used in
the mitogenesis experiments.
Figure 1 Structure of SDZ 62-434.
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Cells were maintained in either RPMI 1640 supplemented
with 2 mM-glutamine and 10% (v/v) foetal calf serum (HL
60, K562, A2780, MCF-7, H69; A2780 cells were also supple-
mented with 0.25 U ml-' insulin) or a 50:50 mixture of
Ham's F1O:DMEM supplemented with 2 mM-glutamine and
10% foetal calf serum (L-DAN, HT29, LoVo, MOG-G-
CCM, SB-18, U251, MOG-G-UVW, Swiss 3T3).
Cell growth
A2780 cells were seeded at 1 x I04in 24 well plates. After
72 h SDZ 62-434 was added at a range of concentrations.
Thereafter the cells were counted every 24 h. Cells were
harvested using trypsin/EDTA (0.25%/i mM) and counted
using an electronic counter (Coulter Electronics).
Cytotoxicity assay
This was carried out using a modification of the method of
Mosmann (1983) as described by Plumb et al. (1989). Cells
were seeded at the appropriate cell density in 96-well plates
and grown for 72 h in a humidified atmosphere of 2% (v/v)
CO2 air at 37°C before addition of a range of SDZ 62-434
concentrations in 200 I of medium. Eight replicate wells
were used for each drug concentration. Cells alone were used
as a control and medium alone was used as a blank. After
24 h the SDZ 62-434 was removed and fresh medium added.
The medium was replaced every 24 h for a further 3 days
allowing the cells to pass through two to three doublings. On
the third day 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium (MTT) (5 mg ml-') was added to each well. The
plates were then incubated in the dark at 37°C for 4 h.
Medium and MTT was then removed and the formazan
crystals (formed following reduction of MTT by live cells)
were dissolved in 200 jLI dimethylsulphoxide and 25 tl
Sorensen's glycine buffer (0.1 M glycine plus 0.1 M NaCl
adjusted to pH 10.5 with 0.1 M NaOH) then added. For the
non-adherent cell lines the plates were centrifuged (1000 g,
5 min) prior to removal of the medium and MTT. The
absorbance was read at 570 nm in an enzyme-linked immuno-
sorbent assay plate reader (Model 2550; Bio-Rad Labora-
tories). Log-concentration response curves were generated
from which ICm values were determined as the concentration
required to inhibit MTT formazan absorbance by 50%.
Clonogenic assay
Cells were plated into 25 cm2 flasks, at a concentration of
7.8 x 104 per flask and grown for 72 h in a humidified atmo-
sphere of 2% (v/v) C02:air at 37°C. The medium was then
removed and fresh medium added containing a range of SDZ
62-434 concentrations. After 24 h the drug was removed and
the cells were harvested using trypsin/EDTA (0.25%/I mM)
and the control cells counted. The control cells were plated at
1 x 103/60 mm plate and the drug-treated cells diluted to the
same extent. The cloning efficiency of the control cells was
between 20 and 25%. The plates were then incubated for 10
days after which the medium was removed and the clones
washed with PBS, fixed in methanol and stained with 0.1%
crystal violet. Colonies of greater than 50 cells were then
counted. Log-concentration response curves were generated
and the IC50 values determined.
Radiolabel incorporation
[3H]Thymidine, [3H]uridine and [3H]leucine incorporation into
acid-insoluble material was used as an indicator of DNA,
RNA and protein synthesis respectively. A2780 cells were
plated at a density of 1 x 103/well in 96 well plates and grown
in a humidified atmosphere of 2% (v/v) CO2 air for 72 h
before addition of a range of SDZ 62-434 concentrations.
Cells were harvested after a 24 h exposure to the drug.
Labelled precursors (0.25 JACi/well) were added for a 1 h
pulse prior to harvesting. The medium was removed and the
cell sheet washed twice with ice-cold phosphate buffered
saline. The cells were then extracted in 0.2 M HC104 at 4°C
for 20 min. After washing in 70% ethanol the cells were
solubilised in 200 jil 0.3 M NaOH. Aliquots (100 ;LI) were
neutralised with an equal volume of 1 m HCI, 4 ml Ecoscint
added and the radioactivity determined using a Packard Tri-
Carb liquid scintillation analyser. Further aliquots were used
for the determination of protein using the Bio-Rad protein
assay kit with bovine serum albumin as a standard. Counts
were normalised for protein content.
1[SCr] Chromatate release assay
This was carried out by a modification of the method of
Wigzell & Ramstedt (1986) as described by Lohmeyer and
Workman (1992). Cells were harvested from log phase cul-
tures using trypsin/EDTA (0.25%/i mM) and counted. The
cells were then labelled by incubating 5 x 106 cells in 0.1 ml
medium containing 100 jCi [5"Cr] sodium chromate for 1 h in
2% CO2 air at 37°C. Following this the cells were then
washed three times with fresh medium, resuspended in
medium and incubated for a further hour. This second
incubation significantly reduced the spontaneous release of
[51Cr]chromate from the cells. The cells were then seeded at
1 x 104/well in 96 well plates in 180 t1 of medium. A range of
drug concentrations were added in 20fd1 of medium. Eight
replicate wells were used for each drug concentration. Con-
trols included cells alone for measurement of spontaneous
release which was < 10% of maximum release and also cells
treated with 0.05% Triton-X 100 added were used to cal-
culate maximum release values. The cells were then incubated
at 37°C for 4 h after which the plates were centrifuged
(1000 g, 5 min) and 100 ,l aliquots of the supernatant
removed for counting using a Packard Cobra II Auto-
Gamma counter.
The percent specific lysis was then calculated as follows:
% Specific Lysis = cpm test sample-cpm spontaneous release
cpm maximum release -cpm spontaneous release
A value of 0% for specific lysis would indicate that the
treatment had no effect above background while a figure of
100% would indicate that lysis was equal to the maximum
effect induced by Triton-X 100.
Mitogenesis experiments
Mitogen stimulation of quiescent Swiss 3T3 cells was carried
out using a modification of the method of Dicker and Rozen-
gurt (1980). Swiss 3T3 cells were plated at I x 103 cells per
30mm plate in FlO:DMEM supplemented with 10% FCS.
After 7 days the medium was replaced with serum-free
medium. At this time the cells were quiescent as determined
by flow cytometry. PDGF (0.95 nM) or bombesin (6.17 nM)
was added in serum-free medium containing 0.1 PCi/plate
[3H]thymidine. When SDZ 62-434 was present it was added
30 min prior to addition of the mitogen and was then present
throughout the experiment. After 40 h at 37°C, [3H]thymidine
incorporation over this period into acid-insoluble material
was determined as described above. Results are expressed as
total radioactivity incorporated.
Results
Cytotoxicity profile ofSDZ 62-434 in different tumour lines
As measured by MTT dye reduction, there was a wide range
of sensitivies (30 fold) to a 24 h exposure of SDZ 62-434 in
both solid and haematological human tumour cell lines
(Table 1). SDZ 62-434 was more active in the three
haematological cell lines (U937, K562, HL60) than in many
of the solid tumour cell lines. However, the colon adrenocar-
cinoma line HT29 and its sub-clone HT29/219 were partic-
ularly sensitive to SDZ 62-434 (ICm 3.6 ± 0.5 and
5.1 ± 0.6 gM respectively), while in another line of similar
origin (LoVo), the ICm was approximately 10 fold higher.
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Table I Cytotoxicity profile of SDZ 62-434 in a range of human
tumour cell lines. Values are the mean ± s.d. of three experiments. In
each experiment the IC50 was calculated using the MTT assay, from
triplicate plates. The drug exposure time was 24 h exposure.
Cell line Origin IC50 (AM)
A2780 Ovarian carcinoma 25.9 ± 9.8
A2780/AD Ovarian carcinoma 74.3 ± 5.6
A2780/CP Ovarian carcinoma 52.0 ± 1.9
L-DAN Squamous non-small 69.3 ± 4.5
H69
MCF-7
MCF-7/AD
HT29
HT29/219
LoVo
MOG-G-CCM
SB-18
U251
MOG-G-UVW
U937
K562
HL60
cell lung carcinoma
Small cell lung
carcinoma
Breast adenocarcinoma
Breast adenocarcinoma
Colon adenocarcinoma
HT29 sub-clone
Colon adenocarcinoma
Astrocytoma
Astrocytoma
Glioblastoma
Astrocytoma
Histiocytic lymphoma
Chronic myelogenous
leukaemia
Promyelocytic
leukaemia
59.1 ± 4.5
111.1 ± 7.6
102.1 ± 9.7
5.1 ± 0.5
3.6 ± 0.6
43.7 ± 2.8
75.9 ± 8.2
66.3 ± 6.5
65.4 ± 3.2
62.3 ± 8.6
31.6±2.8
12.6 ± 1.7
21.4 ± 3.6
.100.
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Figure 2 Comparison of concentration-response curves for SDZ
62-434 cytotoxicity determined by different methods in a, HT29
cells and b, A2780 cells using a 24 h exposure. (U) Clonogenic
assay, (A) MTT assay. Each point represents the mean of three
values. Standard deviations within the experiment were less than
10%. Results are taken from a representative experiment.
The tumour lines of CNS origin had intermediate IC50s in the
range 62-76 JAM. The two lung tumour lines (L-DAN and
H69) exhibited similar sensitivities (59-69 JM) despite their
different histologies. The most resistant line was the MCF-7
Figure 3 Effect of SDZ 62-434 on A2780 cell growth using cell
number as an end point. The arrows indicate the time of addition
and removal of SDZ 62-434. a, SDZ 62-434 was removed after
24 h: control (U), 50 JAM SDZ 62-434 (A), 25 JAM SDZ 62-434
(A), 10 JiM SDZ 620434 (0); b, SDZ 62-434 was present
throughout the experiment: control (M) 301JM SDZ 62-434 (A)
20 JAM SDZ 62-434 (0), 10 JM SDZ 62-434 (0). Each point
represents the mean of triplicate plates. Standard deviations
within the experiment were less than 12%. Results are shown for
a representative experiment.
breast carcinoma with an IC_0 of 11 lJAM. Data obtained in
the cell lines with induced resistance to doxorubicin and
cisplatin (A2780/AD, A2780/CP and MCF-7/AD) are dis-
cussed in a later section.
Results with the MTT assay were compared with IC50
values obtained by a conventional clonogenic assay both
following a 24 h exposure (Figure 2). The IC,0 values for
A2780 and HT29 using the clonogenic assay were 21.0 +
3.5 JM and 6.0 ± 1.5 JAM respectively. There was no signifi-
cant difference in IC50 values obtained by the two methods
using either A2780 or HT29 cells.
Antiproliferative studies in A2780 cells
The A2780 cell lines were used for further studies on the
growth inhibitory properties of SDZ 62-434. SDZ 62-434
produced a concentration-dependent inhibition of A2780 cell
growth using cell number as an end point (Figure 3). Follow-
ing a 24 h exposure to 10 JM SDZ 62-434 there was almost
complete recovery by day 7 (Figure 3a). There was a 24 h
delay following removal of the drug before growth was
reinitiated. Even at high concentrations of SDZ 62-434
(50 JM) there was a slight regrowth at this time. Continual
exposure to SDZ 62-434 resulted in a more efficient growth
inhibition (Figure 3b). Interestingly there was a marked
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reduction in cell number in the drug-treated cells after 96 h
drug exposure (Figure 3b).
Using the MTT assay there was a decrease in the ICm for
SDZ 62-434 with increasing exposure times, up to 48 h, after
which there was no further increase in potency (Table II).
Effect on DNA, RNA and protein synthesis
By looking at radiolabelled precursor incorporation into
A2780 cells we were able to distinguish between SDZ 62-434
effects on DNA, RNA and protein synthesis (Figure 4).
There was very little effect on RNA synthesis, a slight
decrease in protein synthesis at high concentrations, and a
more profound concentration-dependent inhibition of
[H]thymidine incorporation into DNA. The ICs value deter-
mined using this method (34 LM) correlated well with that
seen using the MTT and clonogenic assays.
Cross-resistance and modulation
SDZ 62-434 showed a partial cross-resistance in two drug
resistant variants of the A2780 ovarian carcinoma cell line
(Table I). A resistance factor of 3 was seen in the dox-
orubicin resistant line A2780/AD and factor of 2 in the
cisplatin resistant line A2780/CP using a 24 h drug exposure.
There was no change in the resistance factor to SDZ 62-434
in A2780/AD cells with increasing exposure time (Table II).
In contrast there was no cross-resistance to SDZ 62-434 in
the cisplatin resistant A2780 cells after a 4 h exposure com-
pared with a resistance factor of 3 after a 48 h exposure to
SDZ 62-434 (Table II). There was no difference in the IC50
for the MCF-7 doxorubicin resistant cell line MCF-7/AD
compared to the parental line (Table I). No modulation of
Table II Effect of increasing exposure time on the IC50 of SDZ
62-434 in A2780 cells. Values are mean ± s.d. of three experiments.
In each experiment the ICm was calculated using the MTT assay
following the indicated exposure time to SDZ 62-434. nd, not
determined.
Exposure time IC50 (AM)
(h) A2780 A2780/AD A2780/CP
4 60.3±4.5 128.8 6.9 (2.1) 69.2+ 5.8 (1.1)
24 25.9 9.8 74.3 5.6 (2.7) 52.0 1.9 (2.0)
48 7.3± 1.3 22.4±6.7 (3.1) 24.0±3.1 (3.3)
72 7.1±0.9 18.0±3.9 (2.5) nd
140 -
Z
0
120-
100 -
80-
60-
40-
20-
doxorubicin cytotoxicity was seen in either A2780 or A2780/
AD cells following pretreatment with a sub-cytotoxic concen-
tration of SDZ 62-434 (Figure 5).
Membrane lytic effects
As measured by the [5'Cr]chromate release assay, SDZ 62-434
caused essentially no membrane lysis (,<2%) at concentra-
tions up to 200 LM (Figure 6). A concentration-dependent
membrane lysis was seen in A2780 cells; however this was
only 12% at 200 tLM and <4% at IC50 concentrations(Figure 6 and Table II).
Involvement ofPAF receptors
Treatment of A2780 cells with the potent PAF antagonist
WEB 2086, even at concentrations of up to 200 tLM, had no
cytotoxic effects on A2780 cells using the MTT assay (Figure
7). Pretreatment of these cells with 1001lM WEB 2086 did
not alter the effect of SDZ 62-434 on the growth of the
A2780 cells (Figure 7). This concentration of WEB 2086 was
600 fold greater than that required to inhibit PAF-induced
platelet aggregation by 50% (Casals-Stenzel et al., 1987).
Inhibition of mitogenesis in Swiss 3T3 cells
Both PDGF and bombesin can induce DNA synthesis in
Swiss 3T3 cells quiesced in serum-free medium. PDGF
(0.95 nM) induced levels of DNA synthesis comparable to
120 -
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60-
40 -
20 -
0
0
,
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40-
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a
A2780
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b
A2780/AD
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A. 1
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[SDZ 62-4341 (>M)
Figure 4 Effect of SDZ 62-434 on radiolabelled precursor incor-
poration into A2780 cells. [3H]Thymidine (-), [3H]uridine (-)
and [3H]leucine (A) incorporation was determined following a
24 h exposure to SDZ 62-434. Each point represents the mean of
triplicate plates. Standard deviations were less than 15% within
the experiment. Results are shown for a representative experi-
ment.
0.01 0.1 1 10
[Doxorubicin] (nM)
100 1000
Figure 5 Lack of modulation of doxorubicin cytotoxicity by
SDZ 62-434 in a, A2780 cells; doxorubicin (x), doxorubicin plus
5 tiM SDZ 62-434 (0) and b, A2780/AD cells: doxorubicin (U),
doxorubicin plus 10 gM SDZ 62-434 (0). Log-concentration
curves following a 24 h exposure to doxorubicin were determined
from the mean of triplicate plates using the MTT assay. Standard
deviations within the experiment were less than 12%. Results are
shown for a representative experiment.
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Figure 6 Membrane lytic effects of SDZ 62-434 in HT29 (A)
and A2780 (U) cells. Each point represents the mean of eight
replicate wells. Standard deviations were less than 10% within the
experiment. Results are taken from a representative experiment.
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Figure 8 Inhibition of mitogenesis in Swiss 3T3 cells by SDZ
62-434. Cells were treated with 6.17 nM bombesin, 6.17 nM
bombesin plus 10 I4M SDZ 62-434, 0.95 nM PDGF, 0.95 nM
PDGF plus 10 0MSDZ 62-434 or 10 NMSDZ 62-434 alone.
Values are mean ± s.d. from triplicate plates. Results are taken
from a representative experiment.
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Figure 7 Effect of WEB 2086 on the cytotoxicity of SDZ 62-
4334 in A2780 cells. Log-concentration curves for WEB 2086
(U), SDZ 62-434 (A) and SDZ 62-434 plus 100 IM WEB 2086(0) were determined from the mean of triplicate plates using the
MTT assay. Standard deviations were less then 15% within the
experiment. Results are taken from a representative experiment.
10% foetal calf serum whereas an optimal concentration of
bombesin (6.17 nM) was a less effective mitogen (Figure 8).
At a concentration of 1O pM, SDZ 62-434 had no effect on
basal DNA synthesis in the absence of mitogen. However,
treatment with this concentration of SDZ 62-434 was able to
inhibit both PDGF and bombesin-induced mitogenesis.
Bombesin-induced mitogenesis was inhibited by 86% whereas
the PDGF response was inhibited by 50%. A further experi-
ment was carried out to determine the effects of SDZ 62-434
(10IM) on mitogenesis stimulated by 10% foetal calf serum
compared to the individual mitogens. Serum-stimulated mito-
genesis was inhibited to a similar level (61%) to that induced
by PDGF (56%) and bombesin (82%).
Discussion
The data reported here confirm that the novel imidazoiso-
quinoline PAF antagonist SDZ 62-434 has in vitro antip-
roliferative activity in a range of cell lines from different
human malignancies as originally outlined by Danhauser-
Riedl et al. (1991). These workers reported that SDZ 62-434
showed strong antiprolierative activity in four out of five
solid tumour cell lines and in particular was most active in
the two colorectal adenocarcinomas studied (CCL-218 and
HTB-38). In our study the HT29 colon carcinoma cell line
was also very sensitive to SDZ 62-434, while the other colon
line (LoVo) exhibited intermediate sensitivity within the
panel.
In contrast the same workers showed that SDZ 62-434 was
inactive in five out of six haematological cell lines studied,
while we have shown that SDZ 62-434 is more potent in the
three haematological lines used than in many of the solid
tumour lines. Of interest is the K562 cell line which is
particularly sensitive to SDZ 62-434, but is known to be
resistant to the PAF-related ether lipids (Tidwell et al., 1981).
More detailed studies in A2780 ovarian carcinomas cells
showed that the effects of SDZ 62-434 were concentration-
dependent and exposure time-dependent up to 48 h. After
prolonged exposure times to relatively high concentrations of
SDZ 62-434 a decrease in cell number was seen. Comparison
of MTT data with clonogenic survival in A2780 and HT29
cells confirmed the cell killing potential of SDZ 62-434. The
[5"Cr]chromate release experiments showed that this was not
a non-specific membrane lytic effect. At concentrations much
higher than that required to achieve growth inhibition there
was no membrane damage.
The results show clearly that PAF receptors are not
involved in the mechanism of action of SDZ 62-434. There
are three lines of evidence for this. Firstly, the potent PAF
antagonist WEB 2086 was unable to modulate SDZ 62-434
cytotoxicity. Secondly, functional PAF receptors have only
been identified in a very small number of human tumour cell
lines (Travers et al., 1989; Lee et al., 1990). One of these is
the U937 histiocytic monocyte-like lymphoma cell line (Lee
et al., 1990) while the HL60 promyelocytic leukaemia lym-
phoblast cell line has been shown to possess PAF receptors
only after terminal differentiation (Vallari et al., 1990). Thus
it is clear from our cytotoxicity data that the lack of PAF
receptors does not render cells resistant to SDZ 62-434 (the
IC50 calue in HL60 cells was 21M). Thirdly, the antipro-
liferative activity of SDZ 62-434 and related PAF antagonists
has been shown to exhibit no correlation with inhibition of
PAF-induced human platelet aggregation (Danhauser-Riedl
et al., 1991). In a similar study using other lipid PAF anta-
gonists there was also no correlation between the cytotoxicity
of the antagonists CV 3988 and SRI 63-154 and their ability
to modulate the binding of PAF to human platelets (Berdel
et al., 1987).
Due to the observation of a preferential effect on DNA
synthesis in A2780 cells and in the context of our general
interest in agents which interfere with signalling pathways in
994 V.G. BRUNTON & P. WORKMAN
cancer cells, we studied the effect of SDZ 62-434 on PDGF
and bombesin-induced mitogenesis in quiescent Swiss 3T3
cells. These two mitogens act through different signalling
pathways. The PDGF receptor has intrinsic tyrosine kinase
activity which is activated upon ligand binding (Williams,
1989), whereas the bombesin receptor is linked to a G pro-
tein (Rozengurt, 1990). Our results show that SDZ 62-434 is
able to antagonize the mitogenic effect of both factors at
sensible concentrations. There are many factors involved in
the transduction of a mitogenic signal from the membrane to
the nucleus and which may be blocked by SDZ 62-434,
leading to the inhibition of DNA synthesis observed. Further
studies are currently underway to determine the effect of
SDZ 62-434 on several of the key enzymes involved such as
phospholipase C and protein kinase C in an attempt to
isolate which part of the pathway is blocked by the drug. It
may be that a convergent downstream point such as the
important signalling enzyme protein kinase C (Gescher &
Dale, 1989) is blocked, as serum-stimulated mitogenesis was
also inhibited. Further mitogenic experiments to determine
the relevance of our initial findings in Swiss 3T3 cells to the
specific cytotoxic action of SDZ 62-434 in human tumour cell
lines are underway. However, the results will have to be
interpreted with care as cells may respond to certain
mitogens which may not play an important role in their
growth. For example, MCF-7 cells can be stimulated to
proliferate by bombesin, while there is no strong evidence for
a role of this mitogen in the growth regulation of breast
cancer cells (Nelson et al., 1991).
SDZ 62-434 is an example of a novel structure with inter-
esting pharmacological properties which has entered clinical
trial in cancer patients without a clear understanding of its
mechanism of antitumour action. The development of this
unusual agent would be aided by an elucidation of its cellular
targets. The results reported here suggest that signal trans-
duction pathways represent a fruitful area for further inves-
tigations with SDZ 62-434.
We thank Dr Bill Houlihan for his interest in this work which was
supported by the Cancer Research Compaign (CRC). Paul Work-
man is a CRC Life Fellow.
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